| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 3,110,752 | 2,699,991 | ||
| General and administrative | 2,618,679 | 2,744,545 | ||
| Total operating expenses | 5,729,431 | 5,444,536 | ||
| Loss from operations | -5,729,431 | -5,444,536 | ||
| Interest expense, net | -62,340 | -38,033 | ||
| Change in fair value of warrants | -64,959 | 21,410 | ||
| Merger transaction costs | - | 0 | ||
| Loss on issuance of commitment shares | - | 0 | ||
| Change in fair value of written call option derivative liabilities | - | 0 | ||
| Change in fair value of convertible promissory notes | - | 0 | ||
| Net loss | -5,726,812 | -5,503,979 | ||
| Net loss attributable to common stockholders, basic | -0.03 | -0.03 | ||
| Net loss attributable to common stockholders, diluted | -0.03 | -0.03 | ||
| Weighted-average common stock outstanding, basic | 196,028,784 | 184,307,169 | ||
| Weighted-average common stock outstanding, diluted | 196,028,784 | 184,307,169 | ||
Tevogen Bio Holdings Inc. (TVGNW)
Tevogen Bio Holdings Inc. (TVGNW)